Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury
Milestone Validates Proprietary Neural Repair Discovery Engine and Marks Major Expansion of First-in-Class Endothelin-B Receptor Agonist into a Critical Neurotrauma Indication with Significant Unmet Need
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Vision Alive Max by Holistic Health Labs Features MaquiBright®, the Clinically Studied Maqui Berry Extract at the Research-Matched Dose
- Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments
- Classiq Introduces Fault Tolerance Engine to Bridge Quantum Applications and Fault-Tolerant Hardware
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →